Diabetic retinopathy predicts cardiovascular disease independently of subclinical atherosclerosis in individuals with type 2 diabetes: A prospective cohort study.
cardiovascular disease
diabetic retinopathy
major adverse cardiovascular events
subclinical atherosclerosis
type 2 diabetes
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
05
2022
accepted:
19
10
2022
entrez:
21
11
2022
pubmed:
22
11
2022
medline:
22
11
2022
Statut:
epublish
Résumé
Diabetic retinopathy (DR) and preclinical atherosclerosis are associated with higher cardiovascular risk. However, no studies have investigated the predictive role of DR and preclinical atherosclerosis jointly on cardiovascular events in subjects with type 2 diabetes (T2D). We aimed to assess the contribution of DR and subclinical atherosclerosis on the risk of adverse cardiovascular events in subjects with T2D without previous cardiovascular disease (CVD). We included two prospective cohorts of subjects with T2D from the same geographical area. Assessment of subclinical atherosclerosis was performed by carotid ultrasound. An ophthalmologist classified DR according to standard criteria. Cardiovascular outcomes considered for analysis were the following: ischemic heart disease, stroke, heart failure, peripheral artery disease, revascularization procedures, and cardiovascular mortality. Bivariable and multivariable predictive models were performed. From a total of 374 subjects with T2D 44 developed cardiovascular events during the 7.1 years of follow-up. Diabetes duration, total cholesterol, and glycated hemoglobin (HbA1c) at baseline were higher in subjects who developed cardiovascular outcomes ( DR is a strong predictor of cardiovascular events in T2D individuals at primary CVD prevention, even after accounting for the presence of preclinical carotid atherosclerosis. These results may help to individualize CVD prevention strategies in T2D.
Sections du résumé
Background
UNASSIGNED
Diabetic retinopathy (DR) and preclinical atherosclerosis are associated with higher cardiovascular risk. However, no studies have investigated the predictive role of DR and preclinical atherosclerosis jointly on cardiovascular events in subjects with type 2 diabetes (T2D). We aimed to assess the contribution of DR and subclinical atherosclerosis on the risk of adverse cardiovascular events in subjects with T2D without previous cardiovascular disease (CVD).
Methods
UNASSIGNED
We included two prospective cohorts of subjects with T2D from the same geographical area. Assessment of subclinical atherosclerosis was performed by carotid ultrasound. An ophthalmologist classified DR according to standard criteria. Cardiovascular outcomes considered for analysis were the following: ischemic heart disease, stroke, heart failure, peripheral artery disease, revascularization procedures, and cardiovascular mortality. Bivariable and multivariable predictive models were performed.
Results
UNASSIGNED
From a total of 374 subjects with T2D 44 developed cardiovascular events during the 7.1 years of follow-up. Diabetes duration, total cholesterol, and glycated hemoglobin (HbA1c) at baseline were higher in subjects who developed cardiovascular outcomes (
Conclusion
UNASSIGNED
DR is a strong predictor of cardiovascular events in T2D individuals at primary CVD prevention, even after accounting for the presence of preclinical carotid atherosclerosis. These results may help to individualize CVD prevention strategies in T2D.
Identifiants
pubmed: 36407461
doi: 10.3389/fcvm.2022.945421
pmc: PMC9668891
doi:
Types de publication
Journal Article
Langues
eng
Pagination
945421Informations de copyright
Copyright © 2022 Castelblanco, Granado-Casas, Hernández, Pinyol, Correig, Julve, Rojo-López, Alonso, Avogaro, Ortega and Mauricio.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Medicine (Baltimore). 2017 Jan;96(3):e5894
pubmed: 28099347
J Am Coll Cardiol. 2019 Jun 25;73(24):3210-3227
pubmed: 30423394
Cardiovasc Diabetol. 2015 Mar 18;14:33
pubmed: 25856787
Diabetes Care. 2019 Mar;42(3):e49-e50
pubmed: 30787064
Diabetes Care. 2015 Oct;38(10):1937-44
pubmed: 26253729
Cardiovasc Diabetol. 2019 Jan 10;18(1):2
pubmed: 30630491
Eur Heart J. 2013 Oct;34(39):3035-87
pubmed: 23996285
BMJ Open Diabetes Res Care. 2019 Dec 29;7(1):e000845
pubmed: 31908800
J Diabetes Res. 2018 Dec 16;2018:1631263
pubmed: 30648112
Lancet Diabetes Endocrinol. 2016 Jul;4(7):588-97
pubmed: 27216886
BMC Cardiovasc Disord. 2020 Nov 4;20(1):478
pubmed: 33148188
J Pers Med. 2021 Dec 10;11(12):
pubmed: 34945815
Curr Cardiol Rep. 2017 Mar;19(3):19
pubmed: 28220465
Ophthalmology. 2003 Sep;110(9):1677-82
pubmed: 13129861
Front Endocrinol (Lausanne). 2019 Oct 11;10:689
pubmed: 31681167
Cardiovasc Diabetol. 2017 Jul 27;16(1):95
pubmed: 28750645
Cardiovasc Diabetol. 2020 Mar 31;19(1):43
pubmed: 32234054
Metab Syndr Relat Disord. 2019 Sep;17(7):367-373
pubmed: 31145036
Ann Intern Med. 1999 Mar 16;130(6):461-70
pubmed: 10075613
Diabetologia. 2001 Sep;44 Suppl 2:S54-64
pubmed: 11587051
Nutr Metab Cardiovasc Dis. 2015 Aug;25(8):742-8
pubmed: 26033395
Diabetes Metab Syndr Obes. 2020 Jun 08;13:1911-1920
pubmed: 32606851
Nutr Metab Cardiovasc Dis. 2011 Apr;21(4):286-93
pubmed: 20163939
Diabetes Res Clin Pract. 2012 Apr;96(1):e4-6
pubmed: 22209013
J Invasive Cardiol. 2002 Oct;14(10):599-602
pubmed: 12368513
Diabetes Care. 2017 Mar;40(3):412-418
pubmed: 28223445
Front Med (Lausanne). 2022 Aug 16;9:945245
pubmed: 36052329
Cardiovasc Diabetol. 2019 Nov 16;18(1):159
pubmed: 31733651
Atherosclerosis. 2013 Oct;230(2):399-405
pubmed: 24075774
Cerebrovasc Dis. 2007;23(1):75-80
pubmed: 17108679
J Stroke Cerebrovasc Dis. 2016 Jul;25(7):1688-1695
pubmed: 27068777
Ophthalmology. 2013 Mar;120(3):574-582
pubmed: 23174397
Clin Cardiol. 2017 Sep;40(9):752-758
pubmed: 28543093
Cardiovasc Diabetol. 2018 May 4;17(1):66
pubmed: 29728117
BMC Bioinformatics. 2018 Jul 17;19(1):270
pubmed: 30016950
Diabetes Care. 2021 Jul;44(7):1499-1505
pubmed: 33980605
Diabetes Obes Metab. 2019 Mar;21(3):467-478
pubmed: 30280465
Curr Vasc Pharmacol. 2020;18(2):110-116
pubmed: 30961498
Arch Intern Med. 2004 Sep 27;164(17):1917-24
pubmed: 15451768
Diabetes Obes Metab. 2020 Nov;22(11):2193-2198
pubmed: 32643857